[Short-term neoadjuvant hormone therapy enhanced expression of clusterin in prostate cancer].
OBJECTIVE
To define changes in clusterin expression following short-term neoadjuvant hormone therapy (NHT) and its biological significance in prostate cancer tissues.


METHODS
Twenty-six archival radical prostatectomy (RP) specimens without receiving NHT, 19 needle biopsies and corresponding 19 RP specimens following 3-month NHT, were subjected to immunohistochemical clusterin staining.


RESULTS
Staining for clusterin was mainly found in cytoplasm and part of extracellular matrix. Clusterin expression was significantly greater in RP specimens with preoperative NHT (t = 2.91, P < 0.01); Needle biopsies obtained before NHT consistently demonstrated lower staining intensity (1.42 +/- 0.51) than corresponding RP specimens (2.16 +/- 0.60) following 3-month NHT (t = 7.10, P < 0.01).


CONCLUSIONS
Upregulation of clusterin in part accounts for malignant progression of prostate cancer through its anti-apoptotic action following androgen withdrawal. These findings support that adjuvant therapy targeting clusterin may enhance androgen ablation therapy in advanced prostate cancer.
Niu
Yi-nong
YN
Department of Urology, First Hospital of Peking University, Institute of Urology, Peking University, Beijing 100034, China. farmerniu@163.com
Xin
Dian-qi
DQ
He
Zhi-song
ZS
Zhou
Li-qun
LQ
Pan
Bo-nian
BN
Na
Yan-qun
YQ
Guo
Ying-lu
YL
D000368:Aged; D051152:Clusterin / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000473:pathology / Q000628:therapy*
D051152:Clusterin; D016376:Oligonucleotides, Antisense